

12th IVHEM

INTERNATIONAL VIRAL HEPATITIS
ELIMINATION MEETING



LIVE MEETING | HIROSHIMA, JAPAN | **3-4 SEPTEMBER 2026**



Program

Meeting Organizers



COALITION
FOR GLOBAL
HEPATITIS
ELIMINATION

Local Partners



HIROSHIMA
UNIVERSITY



JIHS
Japan Institute for Health Security



一般社団法人
日本肝臓学会
The Japan Society of Hepatology



Thursday, 3 September 2026

Japan Standard Time (JST)

Opening of the Workshop

- 08:30 **Opening & Welcome**
Huma Qureshi, MD
 Pakistan Medical Research Council, Pakistan
Norihiro Kokudo, MD, PhD, FACS, FRCS
 Japan Institute for Health Security (JIHS), Japan
Mitsuo Ochi, MD, PhD
 Hiroshima University, Japan
Masami Sakoi, MD, MPH
 Ministry of Health, Labour and Welfare, Government of Japan, Japan
John Ward, MD
 Coalition for Global Hepatitis Elimination, Task Force for Global Health /
 Rollins School of Public Health, Emory University, United States

Session 1: Hepatitis Elimination in Asia and Globally: Country Update

Chairs: Kiyohiko Izumi & John Ward

- 08:45 **Pakistan PM's National Program for Elimination of HCV-Updates and Way Forward**
Zia Ullah Khan Dawar, MBBS, PGDHPM, MSc HPM
 UNOPS / Stop TB Partnership (STBP) / Regional Green Light Committee (rGLC) / Global Fund for AIDS, TB & Malaria (GFATM), Pakistan
- 09:05 **Japan - Part 1: Policy & National Framework**
Masami Sakoi, MD, MPH
 Ministry of Health, Labour and Welfare, Government of Japan, Japan
- 09:15 **Japan - Part 2: Epidemiological Status and Elimination Indicators**
Junko Tanaka, PhD
 Hiroshima University, Japan
- 09:25 **China**
Jian Li, PhD
 National Center for AIDS/STD Control and Prevention, China CDC, China
- 09:45 **Discussion**

10:00 Coffee Break

Session 2: Hep B Elimination: Expanding Access to HBV Treatment

Chairs: Tetsuo Takehara & Jessica Howell

- 10:30 **APASL HBV Treatment Guidelines**
George Lau, MBBS(HKU), M.D.(HKU), FRCP(Edin, Lond), FHKAM(Med), FHKCP, FAASLD
 Humanity and Health Clinical Trial Centre, HKSAR, Hong Kong, China
- 10:50 **Roundtable: Operational Research & Experience in Implementing HepB Care Guidelines**
Yoon Jun Kim, MD, PhD
 Seoul National University Hospital / The Korean Association for the Study of the Liver (KASL), South Korea
George Lau, MBBS(HKU), M.D.(HKU), FRCP(Edin, Lond), FHKAM(Med), FHKCP, FAASLD
 Humanity and Health Clinical Trial Centre, HKSAR, Hong Kong, China
Huma Qureshi, MD
 Pakistan Medical Research Council, Karachi, Pakistan
Atsushi Tanaka, MD, PhD
 Teikyo University School of Medicine, Japan
Chia-Jui Yen, MD, PhD
 National Health Insurance Administration (NHIA), Ministry of Health and Welfare, Chinese Taipei



11:25	Short Break	
Oral Abstract Presentations I - Prevention of Mother-to-Child Transmission		
<i>Chairs: Junko Tanaka & Rosmawati Mohamed</i>		
11:30	Longitudinal Follow-up Study of HBV Transmission among Children Born to Pregnant Women Cohort in Siem Reap, Cambodia (2021–2025) Ko Ko - Japan	#1
11:40	Progress Toward Elimination of Mother-to-Child HBV Transmission in Japan: Findings from Nationwide Antenatal Surveillance, 2021–2022 Aya Sugiyama - Japan	#2
11:50	Implementation of WHO Guidelines 2024 for PMTCT of HBV When Viral Load Measurement is Not Accessible Vatthanaphone Latthaphasavang - Laos	#3
12:00	Three-year Clinical and Serological Outcomes Among Children After Maternal Tenofovir Prophylaxis for Hepatitis B in Burkina Faso Serge Ouoba - Japan	#4
12:10	Discussion	
12:30	Lunch Break	
Session 3: Elimination of HBV Mother-to-Child Transmission		
<i>Chairs: Masataka Tsuge & Huma Qureshi</i>		
13:30	Potential of HBcrAg Testing for Stratifying Risk of HCC and Identification of Mothers with High Viral Loads of HBV Tetsuya Hosaka, MD, FAASLD Toranomon Hospital, Japan	
13:50	Whole of Systems Approach to Triple EMTCT: West Bengal, India Pallav Bhattacharya, MBBS STF on Triple Elimination of Hepatitis B Syphilis & HIV, West Bengal, India	
Oral Abstract Presentations II - Micro-Elimination Strategies		
<i>Chairs: Masataka Tsuge & Huma Qureshi</i>		
14:00	Implementing a Micro-Elimination Program for Hepatitis C and Hepatitis B Diagnosis and Referral in Khairpur District, Sindh Province, Pakistan: A Pilot Project for National HCV Elimination Initiative Hassan Mahmood - Pakistan	#6
14:10	Hepatitis D testing Patterns and Prevalence in Australia: a Retrospective Statewide Cohort Study Jessica Howell - Australia	#7
14:20	Hepatitis B, Hepatitis C, and Hepatitis D Epidemiology in Kyrgyzstan – Insights from a Nationwide Population-Based Survey, 2024 Nino Khetsuriani - United States	#8
14:35	Assessing Harm Reduction Equity Across Asian Countries and Territories: A Policy and Service Implementation Index Jana Manning - United States	#9
14:45	Discussion	
15:00	Coffee Break	



Industry-Supported Symposium

AbbVie - A Policy Imperative Central to Elimination: Advancing Hepatitis C Elimination in Carceral Settings Across Asia

Chair: Naoya Sakamoto

- 15:30 **Welcome and Introductions**
Naoya Sakamoto, MD, PhD
Hokkaido University Faculty of Medicine, Japan
- 15:35 **Building a System that Connects HCV Patients to Care on Release from Prison**
Tatsuya Kanto, MD, PhD
The Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS), Japan
- 15:50 **The Last Mile to HCV Elimination: Micro-Elimination Strategies in Chinese Taipei**
Chia-Yen Dai, MD, PhD
Kaohsiung Medical University Hospital, Chinese Taipei
- 16:05 **Panel Discussion and Q&A**
Tatsuya Kanto, MD, PhD
The Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS), Japan
Naoya Sakamoto, MD, PhD
Hokkaido University Faculty of Medicine, Japan
Chia-Yen Dai, MD, PhD
Kaohsiung Medical University Hospital, Chinese Taipei

Session 4: Health Equity: Hepatitis Elimination in the Vulnerable Populations

Chairs: Hideki Aizaki & Carolyn Wester

- 16:15 **HCV treatment for the Incarcerated Persons and Persons Who Inject Drugs**
Jun Inoue, MD, PhD, FAASLD
Institute for Excellence in Higher Education, Tohoku University / Department of Gastroenterology, Tohoku University Hospital, Japan
- 16:35 **HCV Treatment in Incarcerated Settings: Experience in Singapore**
Eugene Wong, MD, MMed, MCI, FRCP, FAMS
Duke-NUS Medical School / Yong Loo Lin School of Medicine / Changi General Hospital, Singapore
- 16:55 **HCV Screening and Linkage to Care for PWUD: Lessons from Korea**
Eun Sun Jang, MD, PhD
Seoul National University, South Korea
- 17:15 **Discussion**

- 17:35 **Poster Viewing & Welcome Reception**



Friday, 4 September 2026

Japan Standard Time (JST)

Session 5: Innovations in Testing, Treatment & Care

Chairs: Takaji Wakita & Charles Gore

- 08:30 **New Therapeutic Options to Achieve Functional Cure of Hepatitis B Virus Infection**
Grace Wong, MBChB (Hons), MD (CUHK), FRCP (Edin), FHKCP, FHKAM (Medicine)
 Chinese University of Hong Kong, Hong Kong, China
- 08:50 **Prospects for Long Acting Therapies to Cure HCV Infection**
Charles Gore
 Medicines Patent Pool (MPP), Switzerland
- 09:10 **From HBcrAg-RDT Development to HBeAg-hs Implementation: a Point-of-Care Strategy to Decentralize HBV PMTCT Eligibility Assessment** #10
Yusuke Shimakawa - France
- 09:20 **Microneedle Array Patch Platform Technology for HBV Vaccination**
Woonsung Na, DVM, PhD
 QuadMedicine, South Korea
- 09:30 **Discussion**

Industry-Supported Symposium II

GSK - Hepatitis B

Chair: Tatsuya Kanto

- 09:50 **Welcome & Introduction**
Tatsuya Kanto, MD, PhD
 The Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS), Japan
- 09:55 **Topics in Hepatitis B**
Masataka Tsuge, MD, PhD
 Hiroshima University Hospital, Japan

10:35 Coffee Break

Oral Abstract Presentations III - Innovations in Testing

Chairs: Tatsuya Kanto & Yoon Jun Kim

- 11:05 **Updated Recommendations for HIV, Hepatitis and STI: A WHO Perspective**
Kiyohiko Izumi, PhD
 World Health Organization, Regional Office for the Western Pacific, Philippines
- 11:25 **Early Real-World Experience Integrating Point-of-Care HBeAg-hs Rapid Testing Into Routine Antenatal Services for HBV PMTCT in The Gambia** #12
Ryoko Asari, Japan
- 11:35 **Integrating Hepatitis B Testing into Existing HIV Infrastructure in Zambia: A Model for Accelerating Micro-Elimination in High HIV-Burden Settings** #13
Alinaswe Bwalya, Zambia
- 11:45 **Discussion**



Industry-Supported Symposium III

Gilead - Beyond Viral Suppression: Reimagining HBV Care for a New Era

Chair: Tetsuo Takehara

12:00 **Panel Discussion**

Tetsuo Takehara, MD, PhD

Kansai Rosai Hospital / The Japan Society of Hepatology, Japan

Yao-Chun Hsu, MD, PhD

Chinese Taipei

Grace Lai-Hung Wong, MBChB (Hons), MD (CUHK), FRCP (Edin), FHKCP, FHKAM (Medicine)

Chinese University of Hong Kong, Hong Kong, China

12:45 **Lunch**

Session 6: Models of Care

Chairs: Norihiro Kokudo & Rosmawati Mohamed

13:45 **Patient-Centered Coordination of Care for HCV: Japan**

Management of HCV-Related Decompensated Cirrhosis in Japan

Tetsuo Takehara, MD, PhD

Kansai Rosai Hospital / The Japan Society of Hepatology, Japan

The role of hub hospitals and regional network systems

Tatsuya Kanto, MD, PhD

The Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS), Japan

14:05 **Age-based Screening: Hong Kong, China**

Bonnie Wong, M.B., Ch.B., MRCP (UK), PDipID, FHKCP, FHKAM(Med), DTM&H(GMITPM), FRCP (Edin)

Department of Health, The Government of The Hong Kong Special Administrative Region, Hong Kong, China

14:25 **Integrated Services & Simplification of Care: Vietnam**

Mayu KONO, MA

Japan International Cooperation Agency (JICA), Japan

14:45 **Discussion: Cost-Effectiveness & Response to Changes in Financing for Global Health**

Oral Abstract Presentations IV - Models of Care

Chairs: Norihiro Kokudo & Rosmawati Mohamed

15:05 **Nationwide Clinical Indicator Monitoring Demonstrates Progress and Remaining Gaps in Standardizing Hepatitis Care in Japan** #15
Hiroko Setoyama, Japan

15:15 **A Cascade-of-Care Analysis for Hepatitis B and C in a 1.9-Million-Person Nationwide Program, Uzbekistan, 2022–2025** #18
Ulugbek Mirzaev, Uzbekistan

15:25 **Discussion**

15:35 **Coffee Break**



Session 7: Next Public Health Threat: Hepatitis-Related Liver Cancer

Chairs: Yoon Jun Kim & Jessica Howell

16:00	Fibulin-3 as a Predictor of Hepatocellular Carcinoma Development During Nucleos(t)ide Analog Therapy in Chronic Hepatitis B Patients Kazuhiro Murai , Japan	#19
16:10	Long-term Transition in Etiology of Liver Cancer in Kyushu, Japan: Impact of Viral Hepatitis Elimination and the Emerging Burden of Non-Viral Liver Disease Hironori Koga , Japan	#20
16:20	Cutting-edge Surgical Treatment for Liver Cancer, Including Liver Transplantation Norihiro Kokudo, MD, PhD, FACS, FRCS Japan Institute for Health Security (JIHS), Japan	
16:40	Q&A	
16:55	Closing Remarks	



GOLD LEVEL SPONSORS

abbvie



GILEAD

GSK

ENDORSERS



